Roland GordonBeresford - Celyad SA Regulatory Affairs and IP Director
| CYAD Stock | EUR 0.72 0.01 1.41% |
Director
Mr. Roland GordonBeresford, Ph.D., has served as Regulatory Affairs and IP Director of Cardio3 Biosciences SA since January 2008. He brings to the Company15 years of experience in managing registrational strategies and processes with pharmaceutical, medical technology and biotechnology products, acquired at BristolMyers Squibb Int. Corporationration and Navigant Biotechnologies among others. He holds a Doctorate in Philosophy in Molecular Biology from the Free University of Brussels, Belgium. since 2008.
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Phone | (32) 10 394 141 |
| Web | www.celyad.com |
Celyad SA Management Efficiency
The company has return on total asset (ROA) of (0.2933) % which means that it has lost $0.2933 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9264) %, meaning that it generated substantial loss on money invested by shareholders. Celyad SA's management efficiency ratios could be used to measure how well Celyad SA manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.93 | |||
| Return On Asset | -0.29 |
Celyad SA Leadership Team
Elected by the shareholders, the Celyad SA's board of directors comprises two types of representatives: Celyad SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celyad. The board's role is to monitor Celyad SA's management team and ensure that shareholders' interests are well served. Celyad SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celyad SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anne Portzenheim, Communication Manager | ||
| Michel Lussier, Chairman of the Board, Co-Founder | ||
| David Georges, VP Admin | ||
| MD MBChB, Chief Officer | ||
| Gaetane Metz, Chief Operating Officer | ||
| Sara Zelkovic, Communications Director | ||
| Jaak Minten, Director Clinical Affairs, representing Fakkel SPRL | ||
| Carri Duncan, Vice President Corporate Development and Communications | ||
| Stephen Rubino, Chief Business Officer | ||
| Hannes Iserentant, Head Property | ||
| Roland GordonBeresford, Regulatory Affairs and IP Director | ||
| BME MBA, CFO, CoFounder | ||
| William Wijns, Non-Executive Director, permanent representative of the Cardiovascular Center Aalst CVBA | ||
| Hanspeter Spek, Non-Executive Director | ||
| Dominic Piscitelli, Independent Director | ||
| Richard Mountfield, Vice President of Global Regulatory Affairs | ||
| JeanMarc Heynderickx, Independent Director | ||
| Frdric Lehmann, VP Affairs | ||
| Peter Waele, Member of the Executive Management Committee, Vice President - Research & Development | ||
| Georges Rawadi, Vice President - Business Development | ||
| Serge Goblet, Non-Executive Director | ||
| Filippo Petti, Chief Executive Officer, Chief Financial Officer, Director | ||
| Louise Proulx, Independent Director | ||
| Maria Koehler, Independent Director | ||
| Philippe Nobels, Chief HR | ||
| Chris Buyse, Independent Director, permanent representative of Life Sciences Research Partners | ||
| An Phan, Head Legal | ||
| Rudy Dekeyser, Independent Director | ||
| Philippe Dechamps, Chief Legal Officer | ||
| Anne Moore, Vice President Corporate Strategy | ||
| Marina UdierBlagovic, Director | ||
| Seron Aymeric, Program Manager | ||
| Margo Roberts, Director |
Celyad Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celyad SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | 11.19 M | |||
| Shares Outstanding | 22.59 M | |||
| Shares Owned By Insiders | 8.83 % | |||
| Shares Owned By Institutions | 24.19 % | |||
| Price To Earning | (22.41) X | |||
| Price To Book | 0.76 X | |||
| Price To Sales | 22,298 X | |||
| Gross Profit | 5 K |
Pair Trading with Celyad SA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celyad SA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celyad SA will appreciate offsetting losses from the drop in the long position's value.Moving against Celyad Stock
| 0.88 | BPOST | Bpost NV | PairCorr |
| 0.82 | GREEN | Greenyard NV | PairCorr |
| 0.81 | IMMO | Immobel | PairCorr |
| 0.76 | ATEB | Atenor SA | PairCorr |
| 0.66 | FOU | Fountain | PairCorr |
The ability to find closely correlated positions to Celyad SA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celyad SA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celyad SA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celyad SA to buy it.
The correlation of Celyad SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celyad SA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celyad SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celyad SA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Celyad Stock Analysis
When running Celyad SA's price analysis, check to measure Celyad SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celyad SA is operating at the current time. Most of Celyad SA's value examination focuses on studying past and present price action to predict the probability of Celyad SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celyad SA's price. Additionally, you may evaluate how the addition of Celyad SA to your portfolios can decrease your overall portfolio volatility.